Allakos(ALLK.US) Officer Sells US$87,934.64 in Common Stock
$Allakos(ALLK.US)$ Officer Radford Harlan Baird sold 87,064 shares of common stock on Jun 28, 2024 at an average price of $1.01 for a total value of $87,934.64.Source: Announcement What is statement o
Allakos Drops After Early-stage Results for Lead Asset
JMP Securities Reiterates Market Outperform on Allakos, Maintains $3 Price Target
JMP Securities analyst Jonathan Wolleben reiterates Allakos (NASDAQ:ALLK) with a Market Outperform and maintains $3 price target.
TD Cowen Maintains Allakos(ALLK.US) With Hold Rating
TD Cowen analyst Joseph Thome maintains $Allakos(ALLK.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 36.3% and a total average return of -10.0% over the past yea
LifeSci Capital Maintains Allakos(ALLK.US) With Hold Rating
LifeSci Capital analyst Sam Slutsky maintains $Allakos(ALLK.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 44.0% and a total average return of 4.6% over the past
JMP Securities Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $3
JMP Securities analyst Jonathan Wolleben maintains $Allakos(ALLK.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 42.7% and a
Allakos Shares Are Trading Lower. The Company Announced Results From the Single and Multiple Ascending Phase 1 Study of Intravenous AK006 in Healthy Volunteers.
Allakos Shares Are Trading Lower. The Company Announced Results From the Single and Multiple Ascending Phase 1 Study of Intravenous AK006 in Healthy Volunteers.
Allakos Reports 'Positive' Results From Phase 1 Trial of Antibody That Inhibits Mast Cells
Allakos (ALLK) reported "positive" results late Tuesday from its single and multiple ascending phase 1 study of intravenous AK006, a monoclonal antibody that selectively inhibits mast cells, in health
Express News | Allakos- in Phase 1 Study Results Ak006 Achieved Serum Concentrations Consistent With Those Showing Mast Cell Inhibition in Preclinical Experiments
Express News | Allakos Inc - Ak006 Showed Dose Linear Exposure and With an Estimated Half-Life of 21 Days for 720 Mg IV Dose
Express News | Allakos Inc - Ak006 Achieved Serum Concentrations Consistent With Levels Demonstrating Inhibitory Activity in Preclinical Experiments
Express News | Allakos Inc: Ak006 Was Well-Tolerated With a Favorable Safety Profile
Express News | Allakos Announces Positive Results From Its Ongoing Phase 1 Trial of Ak006 in Healthy Volunteers, With Ak006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
Cantor Fitzgerald Reiterates Neutral on Allakos
Cantor Fitzgerald analyst Jennifer Kim reiterates Allakos with a Neutral.
Allakos Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/20/2024 — Cantor Fitzgerald Reiterates → Neutral 01/17/2024 175.23% JMP Securities $10 → $3 Maintains
Analysts Offer Insights on Healthcare Companies: Clene (CLNN) and Allakos (ALLK)
Allakos announces first-time patient administration in phase 1 trial of AK006 for chronic spontaneous urticaria
Allakos announces first-time patient administration in phase 1 trial of AK006 for chronic spontaneous urticaria
Allakos Inc - Colorado State University Phase 1 Results Expected to Be Announced by the End of 2024
Allakos Inc - Colorado State University Phase 1 Results Expected to Be Announced by the End of 2024
Express News | Allakos Inc - Top-Line Phase 1 Csu Results Expected at Year End 2024
Express News | Allakos Announces First Patient Dosed in Phase 1 Trial of Ak006 in Chronic Spontaneous Urticaria